• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Johns Hopkins Scleroderma Center

Show Search
Hide Search
  • About The Center
    • Who Are We?
    • How We Are Different
    • About the Area
    • News from the Johns Hopkins Scleroderma Center
  • About Scleroderma
    • Types of Scleroderma
    • Frequently Asked Questions
    • Comprehensive Care
    • Scleroderma Disease Education Video Series
  • For Patients
    • Make An Appointment
    • What To Expect
    • Living with Scleroderma
    • Scleroderma Treatment Options
    • Patient Resources
  • For Physicians
    • Physician Resources
    • Referral Instructions
  • Our Research
    • Publications
    • Clinical Trials
    • Our Research Partners
    • Clinical and Translational Research
  • Donate
Home / Research – Working for a Cure / Clinical Trials

Clinical Trials

The Center is actively participating in clinical trials of new therapies that may improve our patients’ quality of life and better control disease activity.  Current, active clinical trials are listed below.

Current – Active Studies

1) Sildenafil in Early Pulmonary Vascular Disease in Systemic Sclerosis. This study seeks to evaluate whether treatment with sildenafil in scleroderma patients with minimally elevated pulmonary arterial pressures (21-24 mmHg) improves cardiopulmonary outcomes.

We are actively enrolling in this study. This study is being led by our colleagues in the Johns Hopkins Pulmonary Hypertension Center.

2) A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study Evaluating the Safety and Efficacy of Intravenous Iloprost in Subjects With Systemic Sclerosis Experiencing Symptomatic Digital Ischemic Episodes (AURORA Study). 

We are actively enrolling in this study.

3) An open-label extension trial to assess the long term safety of nintedanib in patients with ‘Systemic Sclerosis associated
Interstitial Lung Disease’ (SSc-ILD).

Enrollment is closed.

4) A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Ifetroban in Patients With Diffuse Cutaneous Systemic Sclerosis or Systemic Sclerosis-Associated Pulmonary Arterial Hypertension.

We are actively enrolling in this study.

5) A Phase 2, Randomized, Placebo-controlled, Double-blind, Open-label Extension Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects with Diffuse Cutaneous Systemic Sclerosis.  

We are actively enrolling in this study.

Use of this Site

All information contained within the Johns Hopkins Scleroderma website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.

Primary Sidebar

  • Publications
  • Clinical Trials
  • Clinical and Translational Research
  • Our Research Partners

Footer

Johns Hopkins Rheumatology

  • Johns Hopkins Rheumatology
  • Johns Hopkins Arthritis Center
  • Johns Hopkins Lupus Center
  • Johns Hopkins Lyme Disease Research Center
  • Johns Hopkins Myositis Center
  • Johns Hopkins Sjögren’s Syndrome Center
  • Johns Hopkins Vasculitis Center

Connect With Us

  • Facebook
  • Twitter
  • YouTube
U.S. News and World Report Rankings Badge

Johns Hopkins Medicine

© 2021 Johns Hopkins Scleroderma Center
Patient Privacy